Voyager Therapeutics, Inc. (VYGR) |
|
7.24 -0.51 (-6.58%)
|
10-02 16:00 |
|
Open: |
7.74 |
Pre. Close: |
7.75 |
|
High:
|
7.74 |
Low:
|
7.15 |
|
Volume:
|
371,807 |
Market Cap:
|
318(M) |
|
|
|
Technical analysis |
as of: 2023-10-02 3:53:43 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
|
| Target: |
Six months: 10.66 One year: 12.05 |
| Support: |
Support1: 7.21 Support2: 5.99 |
| Resistance: |
Resistance1: 9.13 Resistance2: 10.31 |
| Pivot: |
7.85 |
| Moving Average: |
MA(5): 7.62 MA(20): 8.19
MA(100): 10.18 MA(250): 8.27  |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 11.9 %D(3): 14.8 |
| RSI: |
RSI(14): 25.9 |
| 52-week: |
High: 14.34 Low: 4.76 |
| Average Vol(K): |
3-Month: 298 (K) 10-Days: 243 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VYGR ] has closed above bottom band by 2.2%. Bollinger Bands are 52.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.87 - 7.9 |
7.9 - 7.94 |
|
Low:
|
7.48 - 7.52 |
7.52 - 7.56 |
|
Close:
|
7.68 - 7.75 |
7.75 - 7.81 |
|
Company Description |
|
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Fri, 29 Sep 2023
Denali Advisors LLC Makes New Investment in Voyager ... - MarketBeat
Mon, 25 Sep 2023
Voyager Therapeutics to Present at the Chardan Genetic Medicines ... - Marketscreener.com
Mon, 25 Sep 2023
Voyager Therapeutics to Present at the Chardan Genetic Medicines ... - GlobeNewswire
Wed, 20 Sep 2023
Voyager Therapeutics, Inc. to Post FY2024 Earnings of ($0.67) Per ... - MarketBeat
Tue, 19 Sep 2023
Performance Analysis of Sectors and Industries in Q3 2023 - Best Stocks
Tue, 12 Sep 2023
Voyager Therapeutics Breaks Below 200-Day Moving Average ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
44 (M) |
| Shares Float |
26 (M) |
|
% Held by Insiders
|
20.7 (%) |
|
% Held by Institutions
|
54.3 (%) |
|
Shares Short
|
2,080 (K) |
|
Shares Short P.Month
|
1,950 (K) |
Stock Financials |
|
EPS
|
2.19 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.55 |
|
Profit Margin (%)
|
49.1 |
|
Operating Margin (%)
|
44.8 |
|
Return on Assets (ttm)
|
21.6 |
|
Return on Equity (ttm)
|
73.9 |
|
Qtrly Rev. Growth
|
581.5 |
|
Gross Profit (p.s.)
|
-0.46 |
|
Sales Per Share
|
4.43 |
|
EBITDA (p.s.)
|
2.08 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
94 (M) |
|
Levered Free Cash Flow
|
7 (M) |
Stock Valuations |
|
PE Ratio
|
3.29 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.58 |
|
Price to Sales
|
1.62 |
|
Price to Cash Flow
|
3.36 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
